



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Correction

# Tackling COVID-19 with neutralizing monoclonal antibodies

Davide Corti,<sup>\*</sup> Lisa A. Purcell, Gyorgy Snell, and David Veesler

<sup>\*</sup>Correspondence: [dcorti@vir.bio](mailto:dcorti@vir.bio)

<https://doi.org/10.1016/j.cell.2021.07.027>

(Cell 184, 3086–3108; June 10, 2021)

During the preparation of the figures for this review, “etesevimab” was mistakenly written as “etesvimab” in Figure 1, and Figure 5C inadvertently indicated the solid red box meant <10-fold loss of neutralization when it should have indicated >10-fold loss. In addition, in Table 1, EUA for VIR-7831/VIR-7832 was indicated for trial NCT04501978 (late treatment), but it should have been indicated for trial NCT04545060 (early treatment). These errors do not affect any results or conclusions described in the review and have been corrected online, and we apologize for any confusion they may have caused.




Figure 1. Timeline of approval of mAbs for all indications (black) and for infectious disease (blue) (corrected)






Figure 1. Timeline of approval of mAbs for all indications (black) and for infectious disease (blue) (original)

**C**

	B.1.1.7 (UK)	B.1.351 (South Africa)	P.1 (Brazil)	B.1.429 (California)	B.1.1.258 (Scotland)	B.1.525 (Nigeria)	B.1.526 (New York)	B.1.617.1 (India)
Casirivimab	Green	Red	Red	Green	Green	Red/White	Red/White	Green
Imdevimab	Green	Green	Green	Green	Red	Green/White	Green/White	Green
Bamlanivimab	Green	Red	Red	Red	Green	Red/White	Red/White	Red
Etesevimab	Green	Red	Red	Green	Green/White	Green/White	Green/White	Green
Sotrovimab	Green	Green	Green	Green	Green	Green	Green	Green
Brii-196	Green	Green	Green/White	Green/White	Green/White	Green/White	Green/White	Green/White
Brii-198	Green	Green	Green/White	Green/White	Green/White	Green/White	Green/White	Green/White
AZD8895	Green	Green	Green	Green	Green/White	Green/White	Green/White	Green/White
AZD1061	Green	Green	Green	Green	Green/White	Green/White	Green/White	Green/White
Regdanvimab	Green	Red	Red/White	Red	Green/White	Green/White	Green/White	Green/White
ADG-20	Green	Green	Green	Green/White	Green/White	Green/White	Green/White	Green/White
BGB-DXP593	Green/White	Green/White	Green/White	Green/White	Green/White	Green/White	Green/White	Green/White
ABBV-47D11	Green	Green	Green	Green	Green/White	Green/White	Green/White	Green/White
ABBV-2B04	Green	Red	Red	Green	Green/White	Green/White	Green/White	Red/White

● Neutralized (<10-fold loss of neutralization)  
● Poorly or not-neutralized (>10-fold loss of neutralization)  
● Predicted to be neutralized  
● Predicted to be weakly or to not be neutralized  
■ Unknown  
 \*Prediction of neutralization coverage is based on the presence of mutations in available epitope of each mAb

Figure 5C. Mutations on the SARS-CoV-2 S in VOCs and resistance profile of clinical mAbs (corrected)

**C**

	B.1.1.7 (UK)	B.1.351 (South Africa)	P.1 (Brazil)	B.1.429 (California)	B.1.1.258 (Scotland)	B.1.525 (Nigeria)	B.1.526 (New York)	B.1.617.1 (India)	
Casirivimab									<ul style="list-style-type: none"> <li> Neutralized (&lt;10-fold loss of neutralization)</li> <li> Poorly or not-neutralized (&lt;10-fold loss of neutralization)</li> <li> Predicted to be neutralized</li> <li> Predicted to be weakly or to not be neutralized</li> <li> Unknown</li> </ul> <p>*Prediction of neutralization coverage is based on the presence of mutations in available epitope of each mAb</p>
Imdevimab									
Bamlanivimab									
Etesevimab									
Sotrovimab									
Brii-196									
Brii-198									
AZD8895									
AZD1061									
Regdanvimab									
ADG-20									
BGB-DXP593									
ABBV-47D11									
ABBV-2B04									

Figure 5C. Mutations on the SARS-CoV-2 S in VOCs and resistance profile of clinical mAbs (original)